Abeona Therapeutics Inc: Upcoming Investor Conference Details
Abeona Therapeutics Inc's Upcoming Investor Conferences
Abeona Therapeutics Inc. (NASDAQ: ABEO) recently announced the participation of its management team in a series of upcoming investor conferences scheduled for September. These events are pivotal for the company's ongoing outreach and investor engagement strategies.
Highlights of Conference Participation
The first event is the Cantor Global Healthcare Conference, taking place on September 4, where the team will engage in a fireside chat at 10:20 a.m. ET, followed by various investor meetings. This format allows for insightful discussions and an exchange of information directly with potential investors.
Presentation at H.C. Wainwright Conference
Following this, the company will be featured in the H.C. Wainwright 27th Annual Global Investment Conference on September 9. At this event, Abeona will deliver a company presentation at 2:00 p.m. ET, also accompanied by investor meetings.
Accessing Live Webcasts
Investors and interested parties can access live webcasts from these important sessions through the Investors section of the Abeona Therapeutics website. The webcasts will not only include live presentations but will also provide on-demand access for those unable to attend live.
About Abeona Therapeutics Inc.
Abeona Therapeutics is a fully integrated, commercial-stage biopharmaceutical firm that focuses on developing innovative cell and gene therapies for serious genetic diseases. Notably, Abeona's flagship product, ZEVASKYN™ (prademagene zamikeracel), is recognized as the world’s first and only autologous cell-based gene therapy intended for the treatment of wounds related to recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe condition.
Manufacturing Excellence
The company's advanced cGMP manufacturing facility is located in Cleveland, serving as the primary site for the commercial production of ZEVASKYN. Such capabilities highlight Abeona's commitment to quality and efficiency in the production of vital therapies.
Future Innovations and Market Potential
Abeona is also advancing its developmental pipeline with next-generation AAV (adeno-associated virus) gene therapies that hold promise for treating a variety of high-unmet medical need conditions, particularly in ophthalmology. The company is currently evaluating innovative AAV capsids aimed at enhancing therapeutic delivery and effectiveness against devastating diseases.
Contact Information
For further information, the primary contact for investor relations at Abeona Therapeutics is Greg Gin, Vice President of Investor Relations and Corporate Communications. Interested parties can reach him via email at ir@abeonatherapeutics.com. This connection provides an essential link for any investor inquiries and follow-ups regarding the company’s strategic direction and innovation initiatives.
Frequently Asked Questions
What conferences will Abeona Therapeutics attend?
Abeona Therapeutics will participate in the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference.
What is ZEVASKYN™?
ZEVASKYN™ is an autologous cell-based gene therapy developed for treating wounds associated with recessive dystrophic epidermolysis bullosa.
Where can I watch the conference webcasts?
The webcasts will be available on the Investors section of the Abeona Therapeutics website under the Events section.
How can I contact Abeona Therapeutics?
For inquiries, you can contact Greg Gin, VP of Investor Relations, at ir@abeonatherapeutics.com.
What is the focus of Abeona Therapeutics' product pipeline?
Abeona is focused on developing cell and gene therapies for serious diseases, with an emphasis on both RDEB and various ophthalmic conditions.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
